OmniAb (OABI) Stock Price, News & Analysis

Company Overview

OmniAb, Inc. is a biotechnology company that develops antibody discovery technologies for use in creating therapeutic medicines. It works with pharmaceutical and biotechnology companies to identify and advance antibody candidates for potential drug development.

Its platform includes genetically engineered animals that can produce antibodies with human characteristics, along with related discovery and screening technologies. These tools are designed to help partners find antibodies for a range of therapeutic targets and applications.

OmniAb became an independent publicly traded company in 2022 through a business combination involving its former parent, Ligand Pharmaceuticals, and Avista Public Acquisition Corp. II. The company’s business is based primarily on collaborations and licenses with partners, which may include payments tied to research, development and commercial milestones, as well as royalties on certain products.

Key Stats

• Today's Range: $4.86 to $5.35
• 50-Day Range: $3.95 to $5.30
• 52-Week Range: $1.35 to $5.45
• Volume: 1.75 million shs
• Average Volume: 1.47 million shs
• Market Capitalization: $743.89 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.50
• Consensus Rating: Moderate Buy

OmniAb Stock Analysis - MarketRank™

OmniAb scored higher than 62% of companies evaluated by MarketBeat, and ranked 444th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

OmniAb has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

OmniAb has a consensus price target of $11.50, representing about 125.5% upside from its current price of $5.10.

Amount of Analyst Coverage

OmniAb has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for OmniAb are expected to grow in the coming year, from ($0.34) to ($0.25) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of OmniAb is -15.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of OmniAb is -15.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

OmniAb has a P/B Ratio of 2.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

6.08% of the float of OmniAb has been sold short.

Short Interest Ratio / Days to Cover

OmniAb has a short interest ratio ("days to cover") of 5.21.

Change versus previous month

Short interest in OmniAb has recently decreased by 6.33%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

OmniAb does not currently pay a dividend.

Dividend Growth

OmniAb does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.61

News Sentiment

OmniAb has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for OmniAb this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for OABI on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, OmniAb insiders have not sold or bought any company stock.

Percentage Held by Insiders

9.80% of the stock of OmniAb is held by insiders.

Percentage Held by Institutions

72.08% of the stock of OmniAb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 10/30/2026
• Today: 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:OABI
• CIK: 1846253
• Web: www.omniab.com
• Phone: 510-250-7800
• Fax: N/A
• Employees: 89
• Year Founded: 2012

Price Target and Rating

• Average Price Target for OmniAb: $11.50
• High Price Target: $12.00
• Low Price Target: $11.00
• Potential Upside/Downside: +125.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.34)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$64.78 million
• Net Margins: -108.11%
• Pretax Margin: -109.12%
• Return on Equity: -16.74%
• Return on Assets: -14.79%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.21
• Quick Ratio: 4.21

Sales & Book Value

• Annual Sales: $18.67 million
• Price / Sales: 39.84
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.71 per share
• Price / Book: 2.98

Miscellaneous

• Outstanding Shares: 145,860,000
• Free Float: 131,566,000
• Market Cap: $743.89 million
• Optionable: Optionable
• Beta: 0.60